# Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Source: https://onco.cc/trials/nct06635447/  
OnCo record `nct06635447` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capivasertib and Fulvestrant in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients is a phase 3 interventional study registered as NCT06635447 by AstraZeneca, with 293 participants enrolled, started 2024-09-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: Capivasertib and Fulvestrant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06635447
- Phase: 3
- Setting: A Phase IIIb Single Arm, 2 Cohorts Study Assessing the Efficacy and Safety of Capivasertib+ Fulvestrant as Treatment for Locally Advanced(Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With Endocrine Therapy in Chinese Patients
- Sponsor: AstraZeneca
- Enrolled: 293

## Sources

- ClinicalTrials.gov NCT06635447: https://clinicaltrials.gov/study/NCT06635447

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capivasertib](https://onco.cc/drugs/capivasertib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06635447.json